Redeye regards Genovis' Q4’20 figures as very firm in the circumstances, confirming the underlying strength of the company and its excellent growth prospects over all horizons. While last year clearly finished on a strong note, we caution that the corona-crisis is not over yet; the start of the new year has obviously been accompanied by new restrictions in several markets. However, Genovis has implemented changes to its marketing practises and appears better positioned to drive new sales through electronic channels. We remain positive to the case, which is fully intact. Our base case is Sek50 per share.